Recent resignation of FDA Commissioner Marty Makary and President Trump’s appointment of Kyle Diamantas as acting commissioner have positioned Diamantas as the clear frontrunner in trader assessments. Diamantas, previously deputy commissioner for the agency’s Human Foods Program, now leads day-to-day operations while the administration evaluates permanent candidates. Other names under consideration include former commissioner Stephen Hahn, former acting commissioner Brett Giroir, senior counselor Sara Brenner, and deputy commissioner Grace Graham, reflecting the White House’s focus on continuity in food safety and regulatory reform priorities. Senate confirmation timelines and potential executive branch preferences continue to shape expectations for a formal announcement.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhậtKyle Diamantas 67%
No announcement by December 31 15.6%
Stephen Hahn 7%
Brett Giroir 3.9%
MỚI
MỚI
Dec 31, 2026
Kyle Diamantas
57%
Stephen Hahn
7%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
16%
Kyle Diamantas 67%
No announcement by December 31 15.6%
Stephen Hahn 7%
Brett Giroir 3.9%
MỚI
MỚI
Dec 31, 2026
Kyle Diamantas
$1,515 KL.
57%
Stephen Hahn
$975 KL.
7%
Brett Giroir
$1,510 KL.
4%
Grace Graham
$1,842 KL.
3%
Sara Brenner
$848 KL.
3%
No announcement by December 31
$425 KL.
16%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent resignation of FDA Commissioner Marty Makary and President Trump’s appointment of Kyle Diamantas as acting commissioner have positioned Diamantas as the clear frontrunner in trader assessments. Diamantas, previously deputy commissioner for the agency’s Human Foods Program, now leads day-to-day operations while the administration evaluates permanent candidates. Other names under consideration include former commissioner Stephen Hahn, former acting commissioner Brett Giroir, senior counselor Sara Brenner, and deputy commissioner Grace Graham, reflecting the White House’s focus on continuity in food safety and regulatory reform priorities. Senate confirmation timelines and potential executive branch preferences continue to shape expectations for a formal announcement.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Thị trường mở: May 12, 2026, 7:59 PM ET
Khối lượng
$7,115Ngày kết thúc
Dec 31, 2026Thị trường mở
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent resignation of FDA Commissioner Marty Makary and President Trump’s appointment of Kyle Diamantas as acting commissioner have positioned Diamantas as the clear frontrunner in trader assessments. Diamantas, previously deputy commissioner for the agency’s Human Foods Program, now leads day-to-day operations while the administration evaluates permanent candidates. Other names under consideration include former commissioner Stephen Hahn, former acting commissioner Brett Giroir, senior counselor Sara Brenner, and deputy commissioner Grace Graham, reflecting the White House’s focus on continuity in food safety and regulatory reform priorities. Senate confirmation timelines and potential executive branch preferences continue to shape expectations for a formal announcement.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Khối lượng
$7,115Ngày kết thúc
Dec 31, 2026Thị trường mở
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Recent resignation of FDA Commissioner Marty Makary and President Trump’s appointment of Kyle Diamantas as acting commissioner have positioned Diamantas as the clear frontrunner in trader assessments. Diamantas, previously deputy commissioner for the agency’s Human Foods Program, now leads day-to-day operations while the administration evaluates permanent candidates. Other names under consideration include former commissioner Stephen Hahn, former acting commissioner Brett Giroir, senior counselor Sara Brenner, and deputy commissioner Grace Graham, reflecting the White House’s focus on continuity in food safety and regulatory reform priorities. Senate confirmation timelines and potential executive branch preferences continue to shape expectations for a formal announcement.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp